HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes

Epigenetics

Volumn 10, Issue 5, 2015, Pages 418-430

  Ooi, Jenny Y Y ^a   Tuano, Natasha K ^a   Rafehi, Haloom ^a,c   Gao, Xiao Ming ^a   Ziemann, Mark ^a   Du, Xiao Jun ^a,b   El Osta, Assam ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cardiac hypertrophy; Chromatin; Epigenetics; HDAC inhibitor; Histone acetylation; Next generation sequencing

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSIN HEAVY CHAIN BETA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRICHOSTATIN A; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CXCL10 GENE; DEACETYLATION; GENE; GENE ACTIVATION; HEART CONTRACTION; HEART VENTRICLE HYPERTROPHY; HISTONE ACETYLATION; IL21R GENE; IL6RA GENE; INFLAMMATION; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TRAF3 GENE; VCAM1 GENE; ACETYLATION; ANIMAL; AORTA; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMEGALY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ACETYLATION; ANIMALS; AORTA; CARDIOMEGALY; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; MALE; MICE, INBRED C57BL; MYOCARDIUM; NF-KAPPA B;

EID: 84954228583     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2015.1024406     Document Type: Article

References (66)

1. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341: 1276-83; PMID:10528039; http://dx.doi.org/10.1056/NEJM199910213411706
2. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010; 128: 191-227; PMID:20438756; http://dx.doi.org/10.1016/j.pharmthera.2010.04.005
3. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart failure reviews 2010; 15: 331-41; PMID:19363700; http://dx.doi.org/10.1007/s10741-009-9140-3
4. Imamura S, Matsuoka R, Hiratsuka E, Kimura M, Nakanishi T, Nishikawa T, Furutani Y, Takao A. Adaptational changes of MHC gene expression and isozyme transition in cardiac overloading. Am J Physiol 1991; 260: H73-9; PMID:1825154
5. Mayer Y, Czosnek H, Zeelon PE, Yaffe D, Nudel U. Expression of the genes coding for the skeletal muscle and cardiac actions in the heart. Nucleic Acids Res 1984; 12: 1087-100; PMID:6546444; http://dx.doi.org/10.1093/nar/12.2.1087
6. McKinsey TA, Olson EN. Cardiac histone acetylationtherapeutic opportunities abound. Trends Genet 2004; 20: 206-13; PMID:15041175; http://dx.doi.org/10.1016/j.tig.2004.02.002
7. McKinsey TA, Olson EN. Dual roles of histone deacetylases in the control of cardiac growth. Novart Found Symp 2004; 259: 132-41; discussion 41-5, 63-9; PMID:15171251; http://dx.doi.org/10.1002/0470862637.ch9
8. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115: 538-46; PMID:15765135; http://dx.doi.org/10.1172/JCI24144
9. McKinsey TA, Zhang CL, Olson EN. Signaling chromatin to make muscle. Curr Opin Cell Biol 2002; 14: 763-72; PMID:12473352; http://dx.doi.org/10.1016/S0955-0674(02)00389-7
10. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/ deacetylation. Novart Found Symp 2006; 274: 3-12; discussion 3-9, 152-5, 272-6; PMID:17019803; http://dx.doi.org/10.1002/0470029331.ch2
11. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 25160; PMID:9305837; http://dx.doi.org/10.1038/38444
12. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-80; PMID:11498575; http://dx.doi.org/10.1126/science.1063127
13. Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herbolsheimer E, et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 2005; 122: 517-27; PMID:16122420; http://dx.doi.org/10.1016/j.cell.2005.06.026
14. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903; PMID:18552846; http://dx.doi.org/10.1038/ng.154
15. Liang G, Lin JC, Wei V, Yoo C, Cheng JC, Nguyen CT, Weisenberger DJ, Egger G, Takai D, Gonzales FA, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci USA 2004; 101: 7357-62.
16. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal responsive repressors of cardiac hypertrophy. Cell 2002a; 110: 479-88; http://dx.doi.org/10.1016/S0092-8674(02)00861-9
17. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007; 13: 324-31; PMID:17322895; http://dx.doi.org/10.1038/nm1552
18. McKinsey TA. The biology and therapeutic implications of HDACs in the heart. Handbook Exp Pharmacol 2011; 206: 57-78; PMID:21879446; http://dx.doi.org/10.1007/978-3-642-21631-2_4
19. Papait R, Cattaneo P, Kunderfranco P, Greco C, Carullo P, Guffanti A, Vigano V, Stirparo GG, Latronico MV, Hasenfuss G, et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci U S A 2013; 110: 20164-9; PMID:24284169; http://dx.doi.org/10.1073/pnas.1315155110
20. Sayed D, He M, Yang Z, Lin L, Abdellatif M. Transcriptional regulation patterns revealed by high resolution chromatin immunoprecipitation during cardiac hypertrophy. J Biol Chem 2013; 288: 2546-58; PMID:23229551; http://dx.doi.org/10.1074/jbc.M112.429449
21. Thaler F, Minucci S. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? Expert Opin Drug Disc 2011; 6: 393-404; PMID:22646017; http://dx.doi.org/10.1517/17460441.2011.557660
22. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003; 278: 28930-7; PMID:12761226; http://dx.doi.org/10.1074/jbc.M303113200
23. Gallo P, Latronico MV, Grimaldi S, Borgia F, Todaro M, Jones P, Gallinari P, De Francesco R, Ciliberto G, Steinkuhler C, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiov Res 2008; 80: 41624; PMID:18697792; http://dx.doi.org/10.1093/cvr/cvn215
24. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006; 113: 51-9; PMID:16380549; http://dx.doi.org/10.1161/CIRCULATIONAHA.105.559724
25. Halsall J, Gupta V, O’Neill LP, Turner BM, Nightingale KP. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors. PloS One 2012; 7: e33453; PMID:22479401; http://dx.doi.org/10.1371/journal.pone.0033453
26. Rada-Iglesias A, Enroth S, Ameur A, Koch CM, Clelland GK, Respuela-Alonso P, Wilcox S, Dovey OM, Ellis PD, Langford CF, et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 2007; 17: 708-19; PMID:17567991; http://dx.doi.org/10.1101/gr.5540007
27. Rafehi H, Balcerczyk A, Lunke S, Kaspi A, Ziemann M, Kn H, Okabe J, Khurana I, Ooi J, Khan AW, et al. Vascular histone deacetylation by pharmacological HDAC inhibition. Genome Res 2014; 24: 1271-84; PMID:24732587; http://dx.doi.org/10.1101/gr.168781.113
28. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y, Rothermel BA, Gillette TG, Hill JA. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A 2011; 108: 4123-8; PMID:21367693; http://dx.doi.org/10.1073/pnas.1015081108
29. Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM, Francis J. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010; 56: 437-44; PMID:20679181; http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.154567
30. Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, Fairlie DP, Brown L. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Brit J Pharmacol 2010; 159: 1408-17; PMID:20180942; http://dx.doi.org/10.1111/j.1476-5381.2010.00637.x
31. Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, Graham RM. Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol 2004; 37: 979-87; PMID:15522275; http://dx.doi.org/10.1016/j.yjmcc.2004.07.010
32. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997; 100: 2362-70; PMID:9410916; http://dx.doi.org/10.1172/JCI119776
33. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-iso form of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 2000; 278: H412-9; PMID:10666070
34. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet: TIG 2008; 24: 133-41; PMID:18262675; http://dx.doi.org/10.1016/j.tig.2007.12.007
35. Park PJ. ChIP-seq: advantages and challenges of amaturing technology. Nat Rev Genet 2009; 10: 66980; PMID:19736561; http://dx.doi.org/10.1038/nrg2641
36. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39: 311-8; PMID:17277777; http://dx.doi.org/10.1038/ng1966
37. Lee CK, Shibata Y, Rao B, Strahl BD, Lieb JD. Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat Genet 2004; 36: 900-5; PMID:15247917; http://dx.doi.org/10.1038/ng1400
38. Sekinger EA, Moqtaderi Z, Struhl K. Intrinsic histone DNA interactions and low nucleosome density are important for preferential accessibility of promoter regions in yeast. Mol Cell 2005; 18: 735-48; PMID:15949447; http://dx.doi.org/10.1016/j.molcel.2005.05.003
39. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137
40. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006; PMID:12045153; http://dx.doi.org/10.1101/gr.229102
41. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
42. Raney BJ, Cline MS, Rosenbloom KR, Dreszer TR, Learned K, Barber GP, Meyer LR, Sloan CA, Malladi VS, Roskin KM, et al. ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res 2011; 39: D871-5; PMID:21037257; http://dx.doi.org/10.1093/nar/gkq1017
43. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-7; PMID:11222463; http://dx.doi.org/10.1161/01.CIR.103.8.1044
44. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-6; PMID:10385494; http://dx.doi.org/10.1161/01.CIR.99.25.3224
45. McKinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011; 17: 434-41; PMID:21267510; http://dx.doi.org/10.2119/molmed.2011.00022
46. Chang L, Kiriazis H, Gao XM, Du XJ, El-Osta A. Cardiac genes show contextual SWI/SNF interactions with distinguishable gene activities. Epigenetics: Off Jo DNA Methylation Soc 2011; 6: 760-8; PMID:21586902; http://dx.doi.org/10.4161/epi.6.6.16007
47. Hang CT, Yang J, Han P, Cheng HL, Shang C, Ashley E, Zhou B, Chang CP. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 2010; 466: 62-7; PMID:20596014; http://dx.doi.org/10.1038/nature09130
48. Haddad F, Qin AX, Bodell PW, Zhang LY, Guo H, Giger JM, Baldwin KM. Regulation of antisense RNA expression during cardiac MHC gene switching in response to pressure overload. Am J Physiol Heart Circ Physiol 2006; 290: H2351-61; PMID:16415074; http://dx.doi.org/10.1152/ajpheart.01111.2005
49. Mathiyalagan P, Okabe J, Chang L, Su Y, Du XJ, El-Osta A. The primary microRNA-208b interacts with Polycomb-group protein, Ezh2, to regulate gene expression in the heart. Nucleic Acids Res 2014; 42: 790-803; PMID:24137001; http://dx.doi.org/10.1093/nar/gkt896
50. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011; 89: 129-38; PMID:20797985; http://dx.doi.org/10.1093/cvr/cvq274
51. Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L, Bergmann MW. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res 2009; 84: 41624; PMID:19620128; http://dx.doi.org/10.1093/cvr/cvp237
52. Gupta S, Young D, Maitra RK, Gupta A, Popovic ZB, Yong SL, Mahajan A, Wang Q, Sen S. Prevention of cardiac hypertrophy and heart failure by silencing of NF-KB. J Mol Biol. 2008; 375:637-49; doi:10.1016/j.jmb.2007.10.006
53. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-KB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011; 89:129-38; doi:10.1093/cvr/cvq274
54. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-KB in the heart: to be or not to NF-KB. Circ Res. 2011; 108:1122-32; doi:10.1161/CIRCRESAHA110.226928
55. Zhang LX, Zhao Y, Cheng G, Guo TL, Chin YE, Liu PY, Zhao TC. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol Heart Circ Physiol 2010; 298: H2154-63; PMID:20382965; http://dx.doi.org/10.1152/ajpheart.01015.2009
56. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-40; PMID:19608861; http://dx.doi.org/10.1126/science.1175371
57. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Invest Drugs 2010; 19: 1049-66; PMID:20687783; http://dx.doi.org/10.1517/13543784.2010.510514
58. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003; 112: 863-71; PMID:12975471; http://dx.doi.org/10.1172/JCI19137
59. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006; 113: 2579-88; PMID:16735673; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.625467
60. McKinsey TA. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol 2011; 51: 491-6; PMID:21108947; http://dx.doi.org/10.1016/j.yjmcc.2010.11.009
61. Nightingale KP, O’Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 2006; 16: 125-36; PMID:16503131; http://dx.doi.org/10.1016/j.gde.2006.02.015
62. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003; 15: 172-83; PMID:12648673; http://dx.doi.org/10.1016/S0955-0674(03)00013-9
63. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 2007; 282: 4408-16; PMID:17166833; http://dx.doi.org/10.1074/jbc.M606773200
64. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-60; PMID:19451168; http://dx.doi.org/10.1093/bioinformatics/btp324
65. Kuhn RM, Haussler D, Kent WJ. The UCSC genome browser and associated tools. Briefings Bioinformatics 2012; 14: 144-61; PMID:22908213
66. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010; 26: 841-2; PMID:20110278; http://dx.doi.org/10.1093/bioinformatics/btq033i